Sign In
Buy ZBIO
$17.40
+0.270 (+1.58%)
At Close: Jun 03, 2026
NEW YORK , March 21, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zenas BioPha
Rosen Law Firm Encourages Zenas BioPharma, Inc. Investors to Inquire About Securities Class Action Investigation – ZBIO
03:30pm, Thursday, 20'th Mar 2025
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zenas BioPharma, Inc. (NASDAQ:
Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer
07:05am, Monday, 17'th Mar 2025
–Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies–
- Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x FcγRIIb inhibitor of B cell function- -Topline results from Phase 2 Trial in Relapsing Multiple Sclerosis (MoonStone) expected i
Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference
08:00am, Tuesday, 28'th Jan 2025
WALTHAM, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader
Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
07:10am, Tuesday, 12'th Nov 2024
-Completed initial public offering, raising $258.7 million in gross proceeds, to fund the expanded clinical development of lead product candidate, obexelimab, and support company growth strategy-
-INDIGO is the largest clinical trial conducted in patients living with IgG4-RD- -Topline INDIGO results expected by the end of 2025- WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma,
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences
07:05am, Thursday, 07'th Nov 2024
WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader
Last Week's 3 Biotech IPOs Prompt Huge Insider Buying
09:15am, Sunday, 22'nd Sep 2024
24/7 Wall St. Insights Initial public offerings at three biotechs last week tempted insiders to make huge purchases of shares.
Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering
04:15pm, Thursday, 19'th Sep 2024
WALTHAM, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development
U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market
05:00am, Saturday, 14'th Sep 2024
Six IPOs debuted this past week, including three deals of more than $100 million. Seven IPOs submitted initial filings. Outparcel REIT FrontView REIT filed to raise $100 million, and Chinese on-demand
Zenas BioPharma Announces Pricing of Upsized Initial Public Offering
10:37pm, Thursday, 12'th Sep 2024
WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development
U.S. IPO Weekly Recap: 2 APAC Microcaps Go Public In Short Labor Day Week As The Pipeline Grows
01:25am, Saturday, 07'th Sep 2024
Two small IPOs and two SPACs debuted this past week - Pheton Holdings, Powell Max, Vine Hill Capital, and Andretti Acquisition II, respectively. Eight IPOs submitted initial filings this past week, in
Zenas BioPharma Seeks IPO For Inflammatory Treatment Trials
11:11am, Monday, 26'th Aug 2024
Zenas BioPharma has filed to raise $100 million in an IPO to advance its Phase 3 and Phase 2 trials for obexelimab, although the final figure may differ. The company is developing antibody-based treat
U.S. IPO Weekly Recap: WeRide Delays Its IPO As Pipeline Gets A Boost
05:00am, Saturday, 24'th Aug 2024
Two small IPOs debuted this past week, while six IPOs submitted initial filings. Six IPOs submitted initial filings this week, including four names which filed to raise $100 million or more. There are
